HR4780-119

What This Bill Does

The USTRx Act responds to foreign pharmaceutical price controls that Congress says depress prices for innovative drugs abroad, reduce incentives for new medicines, shift development costs to American patients and taxpayers, and restrict access to treatments. It amends the Trade Act of 1974 to add a Chief Pharmaceutical Trade Negotiator alongside the Chief Agricultural Negotiator. The new negotiator's principal functions are to conduct trade negotiations, enforce trade agreements involving U.S. pharmaceutical products, and take appropriate action against acts, policies, or practices of high-income countries that significantly harm U.S. pharmaceutical manufacturers' full market access. The negotiator must advocate for U.S. pharmaceutical manufacturers and consumers and consult or coordinate with the Chief Intellectual Property Negotiator as appropriate. USTR must annually compile and update a list of countries classified as high income by World Bank statistics. For each listed country, USTR, through the Chief Pharmaceutical Trade Negotiator, must annually report to House Ways and Means and Senate Finance and publish on USTR's website a detailed review of pharmaceutical trade practices from the prior fiscal year. The report must determine whether country practices are unfair, discriminatory, nontransparent, non-market-based, undervalue innovative medicines, deny reciprocal market access, reduce innovation incentives, violate trade agreements, deny U.S. benefits, or impose unjustifiable, unreasonable, discriminatory, or significant burdens on U.S. commerce. It must also describe responsive U.S. actions from prior reports. Within 30 days after USTR determines that a listed country's practice meets the adverse criteria, USTR must submit a response plan to the tax-writing committees, which may include initiating a section 301 investigation.

Who Benefits and How

U.S. pharmaceutical manufacturers benefit from a dedicated USTR negotiator focused on foreign pricing and market-access barriers. U.S. drug innovation investors benefit if trade pressure increases returns from high-income foreign markets. American patients benefit if the policy succeeds in increasing global contribution to drug development and sustaining new treatment access. Congressional trade committees benefit from annual country reports and 30-day response plans.

Who Bears the Burden and How

U.S. Trade Representative must create the negotiator function, maintain high-income country lists, publish annual reports, and submit response plans. High-income foreign governments with price controls face U.S. trade scrutiny and potential section 301 investigations. Chief Pharmaceutical Trade Negotiator must conduct negotiations, enforce agreements, and coordinate with intellectual property officials. Foreign pharmaceutical payers may face pressure to change reimbursement or price-control policies.

Key Provisions

• Creates a Chief Pharmaceutical Trade Negotiator in USTR.
• Requires annual lists of World Bank high-income countries.
• Requires annual public reviews of listed countries' pharmaceutical trade, reimbursement, pricing, innovation, and market-access practices.
• Requires 30-day response plans when USTR finds practices harming U.S. interests.
• Authorizes response plans to include section 301 investigations.